An international consortium of 48 researchers from institutions in France, Sweden, and the United States has won the 2025 edition of the ...

The move might at first sound like little more than a reduced hassle—and maybe reckless, since there was good evidence in ...

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies. While trastuzumab deruxtecan has shown superior activity ...

Deep in the folds of the intestine, in microscopic pockets called crypts, a quiet surveillance system is always at work. Stem ...

Although progression-free survival was similar across racial groups, overall survival was shorter for Black patients with ...

A team of researchers has clarified a biological process first observed more than 50 years ago: how tissues rebuild ...

A mysterious RNA found in breast cancer led scientists to uncover an entire hidden class of cancer-specific RNAs across ...

Researchers analyzed data from 1,903 patients with stage 3 or stage 4 epithelial ovarian cancer who were enrolled in four ...

HER2-positive gastric cancer accounts for a substantial proportion of advanced cases and has long been treated with HER2-targeted therapies.

Researchers have resolved a 50-year-old scientific mystery by identifying the molecular mechanism that allows tissues to ...

A companion diagnostic test was simultaneously approved to identify eligible patients whose tumors express PD-L1 with a combined positive score of 1 or higher.

As Merck received its latest FDA nod for Keytruda in ovarian cancer, Agilent gained the green light for its accompanying test to identify patients who can best benefit from the drug.  | As Merck ...